<DOC>
	<DOCNO>NCT01160237</DOCNO>
	<brief_summary>The aim study evaluate immune response safety one injection FluarixTM/ Influsplit SSW® 2010/2011 Pandemrix TM subject receive single Pandemrix TM dose least 6 month precede study inclusion . Subjects never vaccinate H1N1 pandemic vaccine enrol control . This Protocol Posting update follow Amendment Protocol , July 2010 . The impacted section entry criterion .</brief_summary>
	<brief_title>Study Evaluate Immune Response Safety Fluarix TM/ Influsplit SSW® 2010/2011 Pandemrix TM</brief_title>
	<detailed_description />
	<criteria>Subjects investigator believe comply requirement protocol . Specific attention give compliance potential subject suspect known drug alcohol abuse . Subjects receive one dose Pandemrix least 6 month enrolment , enrol Groups A B OR subject previously vaccinate vaccine pandemic H1N1 strain , enrol group C. A male female 18 year time enrolment . Written inform consent obtain subject . Healthy subject free acute aggravation health status establish physical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study . Use investigational nonregistered product study vaccine within 30 day precede dose study vaccine , plan use study period . Administration influenza vaccine within 6 month prior vaccination study . Presence evidence substance abuse neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence axillary temperature ≥ 37.5ºC , acute symptom great `` mild '' severity schedule date first vaccination . Diagnosed cancer , treatment cancer , within past 3 year . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Chronic administration immunosuppressant immune modify drug within 6 month study enrolment plan administration study period.. Any administration longacting immunemodifying drug ( within 3 month study start , plan administration study period . Receipt immunoglobulins and/or blood product within 3 month study enrolment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome . Clinically virologically confirm influenza infection within 6 month precede study start . Administration vaccine within 30 day vaccination . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction constituent influenza vaccine ; history severe adverse reaction previous influenza vaccine . Pregnant lactate female Female planning become pregnant planning discontinue contraceptive precaution study inclusion 2 month completion vaccination series . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>H1N1</keyword>
	<keyword>Pandemrix</keyword>
	<keyword>Fluarix</keyword>
	<keyword>Influenza</keyword>
</DOC>